DE68908913T2 - Faktor XIII zur Vorbeugung von intraventrikulären Blutungen. - Google Patents

Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.

Info

Publication number
DE68908913T2
DE68908913T2 DE89102471T DE68908913T DE68908913T2 DE 68908913 T2 DE68908913 T2 DE 68908913T2 DE 89102471 T DE89102471 T DE 89102471T DE 68908913 T DE68908913 T DE 68908913T DE 68908913 T2 DE68908913 T2 DE 68908913T2
Authority
DE
Germany
Prior art keywords
factor xiii
precipitate
intraventricular
bleeding
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE89102471T
Other languages
German (de)
English (en)
Other versions
DE68908913D1 (de
Inventor
Akira Shirahata
Satoshi Tanaka
Kenichiro Tsumura
Minoru Uchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of DE68908913D1 publication Critical patent/DE68908913D1/de
Publication of DE68908913T2 publication Critical patent/DE68908913T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE89102471T 1988-02-24 1989-02-14 Faktor XIII zur Vorbeugung von intraventrikulären Blutungen. Expired - Lifetime DE68908913T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤

Publications (2)

Publication Number Publication Date
DE68908913D1 DE68908913D1 (de) 1993-10-14
DE68908913T2 true DE68908913T2 (de) 1994-01-27

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89102471T Expired - Lifetime DE68908913T2 (de) 1988-02-24 1989-02-14 Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.

Country Status (12)

Country Link
US (1) US5114916A (enExample)
EP (1) EP0330049B1 (enExample)
JP (1) JPH01216939A (enExample)
KR (1) KR0137476B1 (enExample)
AT (1) ATE94070T1 (enExample)
AU (1) AU613154B2 (enExample)
CA (1) CA1332352C (enExample)
DE (1) DE68908913T2 (enExample)
DK (1) DK174978B1 (enExample)
ES (1) ES2059588T3 (enExample)
IE (1) IE63656B1 (enExample)
PT (1) PT89802B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
JP3550685B2 (ja) * 1992-04-21 2004-08-04 味の素株式会社 創傷治療剤
ES2139729T3 (es) * 1992-11-12 2000-02-16 Zymogenetics Inc Uso del factor xiii aplicado topicamente para la inhibicion de hemorragias.
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
DE69925917T2 (de) 1998-08-06 2006-05-11 Mountain View Pharmaceuticals, Inc., Menlo Park PEG-Urikase Konjugate und Verwendung davon
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
AU2005308830B2 (en) * 2004-11-23 2012-01-19 Zymogenetics, Inc. Purification of recombinant human factor XIII
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
CN101622270B (zh) * 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
BRPI1010069A2 (pt) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DE3751269T2 (de) * 1986-09-19 1995-09-14 Univ Washington Expression des biologisch aktiven Faktors XIII.

Also Published As

Publication number Publication date
KR0137476B1 (ko) 1998-06-01
ATE94070T1 (de) 1993-09-15
EP0330049A3 (en) 1991-01-30
JPH0378850B2 (enExample) 1991-12-17
EP0330049A2 (en) 1989-08-30
AU3024389A (en) 1989-08-24
IE63656B1 (en) 1995-05-31
KR890012659A (ko) 1989-09-18
DE68908913D1 (de) 1993-10-14
PT89802A (pt) 1989-10-04
ES2059588T3 (es) 1994-11-16
CA1332352C (en) 1994-10-11
DK83889A (da) 1989-08-25
IE890580L (en) 1989-08-24
US5114916A (en) 1992-05-19
DK174978B1 (da) 2004-04-05
JPH01216939A (ja) 1989-08-30
PT89802B (pt) 1994-04-29
EP0330049B1 (en) 1993-09-08
AU613154B2 (en) 1991-07-25
DK83889D0 (da) 1989-02-23

Similar Documents

Publication Publication Date Title
DE68908913T2 (de) Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.
US4340589A (en) Antithrombin preparation and process for the production thereof
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE3856321T2 (de) Sulfatierte Polysaccharide mit antiinflammatorischer Aktivität
DE60024415T2 (de) Glycin-betain zumr antithrombotischen gebrauch
EP0052827B1 (de) Verfahren zur Herstellung von Blutgerinnungsfaktoren und danach hergestellte Präparation der Faktoren II und VII
CH664495A5 (de) Pharmazeutische formulierung.
US5561109A (en) Method for the healing of wounds caused by corneal injury
EP0430200A1 (de) Arzneimittel zur subkutanen oder intramuskulären Applikation enthaltend Polypeptide
DE69321007T2 (de) Zusammensetzung zur Stabilisierung von Blutplasma im Laufe der Pasteurisation und Pasteurisationsverfahren unter Verwendung dieser Zusammensetzung
US6720011B1 (en) Injectable composition for cancer treatment
EP0514367B1 (de) Arzneimittel enthaltend Protein C
DE69326627T2 (de) Therapeutisches Mittel gegen drohenden Abortus
DE3876817T2 (de) Anwendung des humanblut-koagulationsfaktors-xiii zur behandlung von colitis gravis.
JPH01151514A (ja) 神経疾患治療・予防剤
DE69330960T2 (de) Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
DE69431430T2 (de) Faktor XIII zur Behandlung von Hautwunden
DE69113437T2 (de) Therapeutische Mittel für diabetisches Gangrän.
EP0119990A2 (de) Verfahren zur Herstellung von therapeutisch verabreichbaren, in Endbehältern abgefüllten Plasmaderivaten
DE69905489T2 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69117920T2 (de) Zusammensetzung zur stabilisierung von blutplasma im laufe der pasteurisation
DE68913212T2 (de) Ein reines faktor i-protein und verfahren zur herstellung.
DE69838399T2 (de) Präparation zur kontinuierlichen intravenösen verabreichung
Burrage et al. Maintenance cortisone in severe bronchial asthma
EP0733371B1 (de) Mittel zur subkutanen Verabreichung von Protein C

Legal Events

Date Code Title Description
8364 No opposition during term of opposition